Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of MCS-5 in Treating Male Oligoasthenospermia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male subjects who are 20 years old or older~2. Subjects who are diagnosed as idiopathic oligoasthenospermia~3. Subjects who have a normal baseline hormone profile~4. Subjects who were not able to impregnate female partners in the past 12 months under an active and unprotected sexual life~5. Subject's female partner has no endocrine or genital obstructive disorders and is capable of impregnation.~6. Subjects who have an acceptable baseline liver function~7. Subjects who have a normal baseline renal function.~Exclusion Criteria:~1. Subjects who have been diagnosed as male infertility for more than 5 years.~2. Subjects who have a baseline semen white blood cell count of 1\*106/mL.~3. Subjects who have genital/seminal tract obstruction, infection, inflammation or anatomic abnormalities.~4. Subjects whose female partner has been diagnosed as infertility of any kind.~5. Male infertility that is associated with hormonal deficiency/imbalance, poor nutrition, congenital/chromosomal disorders, erectile dysfunction, or psychological disorders.~6. Subjects who plan to undergo artificial insemination of any kind within the study period.~7. Subjects who have been treated with chemotherapy, pelvic irradiation or major pelvic surgery~8. Subjects who will undergo any invasive procedures within the study period~9. Subjects who will undergo any chemotherapy or radiotherapy of any kind during the study period.~10. Subjects who can not or are not willing to undergo the two-week wash-out period for any reasons.

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- MCS-5 (Type: ACTIVE_COMPARATOR): Group 1: MCS-5 5 mg/day for 16 weeks;Group 2: MCS-5 10 mg/day for 16 weeks;Group 3: MCS-5 20 mg/day for 16 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Group 4: Placebo for 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).